Satsuma Pharmaceuticals, Inc.
DelistedCIK 1692830fmd_0SKV7RS0DYMFDVK1MV9EMQWS1QManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2017 to Mar 31, 2023, 22 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|
| Research and development | 4 | 6 | 24 | 36 | 38 | 44 |
| Total operating expenses | 5 | 8 | 29 | 48 | 51 | 71 |
| Operating income | (5) | (8) | (29) | (48) | (51) | (71) |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest and investment income | 0 | 0 | 1 | 1 | 0 | 1 |
| Other non-operating income (expense) | (0) | 0 | (0) | – | – | – |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | (5) | (7) | (28) | (48) | (51) | (70) |